Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP), the pharmaceutical company developing prescription cannabinoid medicines, is pleased to announce that it has commenced its phase I clinical trial for the lead drug candidate, OCT461201, marking the administration of the first human dose.
OCT has also bolstered its advisory team with the appointment of Dr William Paul Farquhar- Smith, a recognised expert in Chemotherapy Induced Peripheral Neuropathy (“CIPN”). He is a consultant in pain medicine and anaesthetics at The Royal Marsden Foundation NHS Trust, leading the UK's only dedicated CIPN clinic.
Read the full story here.
Date posted: 27 July 2023
Article tag: Oxford Cannabinoid Technologies
Share